Trials / Completed
CompletedNCT00051103
Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.
An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects With Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving Herceptin Containing Regimens
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the efficacy of an oral investigational drug for the treatment of metastatic breast cancer tumors that are known to overexpress HER2/neu.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Investigational Cancer Drug |
Timeline
- Start date
- 2002-10-01
- Primary completion
- 2005-06-01
- Completion
- 2005-06-01
- First posted
- 2003-01-06
- Last updated
- 2015-04-15
Locations
30 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00051103. Inclusion in this directory is not an endorsement.